Board of Directors

Board of Directors

Corporate Governance | Executive Management Team | Board of Directors | Other Committees

 

Mark L. Weinstein, President and Chief Executive Officer, BioClinica

Mr. Weinstein has been a director of BioClinica since March 1998 and has served as the President and Chief Executive Officer of BioClinica since February 1998.  Mr. Weinstein also served as the Chief Financial Officer of BioClinica from January 31, 2000 to February 18, 2003.  Mr. Weinstein joined BioClinica in June 1997 as Senior Vice President, Sales and Marketing and was appointed Interim Chief Executive Officer in December 1997.  Prior to joining BioClinica, from September 1996 to May 1997, he was the Chief Operating Officer of Internet Tradeline, Inc., an internet-based electronic solutions provider.  From July 1991 to August 1996, Mr. Weinstein worked for Medical Economics Company, an international health care information company and wholly-owned division of The Thomson Corporation.  He held several senior management positions at Medical Economics Company with his last position being President and Chief Operating Officer of the International Group.  Mr. Weinstein received his MBA from College of William and Mary and his Bachelor’s degree in Economics from University of Virginia.

Jeffrey H. Berg, Ph.D., President, Health Care Insights

Dr. Berg has been a director of BioClinica since January 1994, and is currently the President of Health Care Insights, a healthcare research and consulting firm.  Dr. Berg has been President of Health Care Insights since March 1991.  From February 2004 until April 2005, he was the Director of Medical Technology for Crystal Research Associates.  He was an analyst for HCFP/Brenner Securities from May 2002 to January 2004.  From September 1995 to May 2002, Dr. Berg was a senior research analyst for MH Meyerson, a brokerage firm.  While President of Health Care Insights, from January 1994 to June 1995, Dr. Berg also served as a financial analyst for GKN Securities Corp., an investment banking firm which served as the underwriter in the Company's June 1992 public offering, and was a financial analyst from March 1992 until December 1992 for The Chicago Corporation, a brokerage firm.   For the past 15 years, Dr. Berg has been a Contributing Editor to the Biomedical Business & Technology newsletter, published by AHC Media.  Dr. Berg received a PhD in organic chemistry from New York University’s Graduate School of Arts and Science and san MBA from its Graduate School of Business Administration and received his Ph.D.  He has a BS from Yeshiva College.

E. Martin Davidoff, CPA, Esq., E. Martin Davidoff and Associates

Mr. Davidoff has been a director of BioClinica since May 2004 and has operated his own tax practice, as both a certified public accountant and tax attorney, since 1981.  He currently serves as the Immediate Past-President of the American Association of Attorney-Certified Public Accountants (AAA-CPA), is founder of the Internal Revenue Service Tax Liaison Committee and Chair for the IRS Liaison Sub-Committee on Legislative Affairs for the AAA-CPA. As a member of the AICPA's Tax Division, he has served on their Tax Legislative Liaison Committee.  He completed two years on the Executive Committee of the New Jersey Society of Certified Public Accountants (“NJSCPA”), having served as the organization's Secretary and as Vice President for Taxation and Legislation.  Mr. Davidoff has also served as President of the Middlesex/Somerset chapter of the NJSCPA and as the chairman of the NJSCPA Federal Taxation and Membership Committees.  He is a member of the tax section of the New Jersey Bar Association.  In 1995, Mr. Davidoff was appointed by then Governor Christine Todd Whitman to the White House Conference on Small Business.  Among the honors he has received are the 1998/1999 New Jersey Society of CPAs Distinguished Service Award for his dedicated service and commitment to the Society; the SBA 1997 Accountant Advocate of the Year for New Jersey and Region II (New York, New Jersey, Virgin Islands, and Puerto Rico); and the 1998 Nicholas Maul Leadership Award from the Middlesex County Regional Chamber of Commerce.  Selected as one of the 2004, 2005, 2006, 2007, 2008 and 2009 Top 100 Most Influential People in Accounting by Accounting Today, the editions noted that “Davidoff’s views on issues affecting tax practice are heard at the highest levels of government.”  CPA Magazine has also chosen Mr. Davidoff as one of the Top 50 IRS Practitioners of 2008 in their April/May 2008 edition and one of the Top 40 Tax Advisors To Know During a Recession in their April/May 2009 edition. Mr. Davidoff received his undergraduate degree from Massachusetts Institute of Technology, an MBA from Boston University Graduate School of Management, and a JD from the Washington University School of Law.

James A. Taylor, Ph D., President Taylor Associates

Dr. Taylor has been a director of BioClinica since October 1994, has been a partner at Merchant-Taylor International, Inc., a bio-pharmaceutical consulting firm, since May 1995 and has been President of Taylor Associates, a regulatory and product development consulting firm since October 1992. From 1987 to 1992, Dr. Taylor was Vice President and Chief Regulatory Officer of ImmunoGen Inc., a pharmaceutical company.  From 1983 to 1987, he was Vice President, Regulatory Affairs of Carter-Wallace, Inc.  Prior to that, Dr. Taylor was employed in various capacities by ICI Pharmaceuticals for four years and Pfizer Central Research for 12 years. Dr. Taylor holds Ph.D. and Master’s degrees in Biochemistry from Purdue University and a Bachelor’s degree in Chemistry from Providence College.

David E. Nowicki, D.M.D., Chairman of the Board, BioClinica

Dr. Nowicki has been a director of BioClinica since July 1998 and was appointed Chairman of the Board of Directors of BioClinica in October 1999.  Dr. Nowicki has had a private practice in periodontics and dental implants since September 1981.  Dr. Nowicki received his DMD from the University of Medicine and Dentistry of New Jersey in 1976.  He completed his postdoctoral training in Periodontology in 1978 and subsequently served on the postgraduate faculty of the University of Medicine and Dentistry of New Jersey as an associate clinical professor.  He has lectured nationally about periodontology, computer imaging for implant surgery, and systems thinking in health care.

Richard F. Cimino, President Clinical Development Services and Corporate Senior Vice President, Covance, Inc.

Mr. Cimino has been a Director of BioClinica since February 2005.  Mr. Cimino joined Covance, Inc. in December 2003.  He is President, Clinical Development Services and Corporate Senior Vice President of Covance and is responsible for the global Phase I-III Development Services businesses.  Mr. Cimino is a member of the Global Leadership Council, and reports to the Chief Operating Officer.  Prior to joining Covance, Mr. Cimino was General Manager, Americas Health Imaging and Corporate Vice President of the Eastman Kodak Company from January 2001 to July 2003.  Prior to that time, he held senior management positions in multiple lines of business over a 20-year career at Kodak. These included General Manager for the Health Group's Americas business. In addition, he was the Chief Marketing Officer for the Health Group responsible for Global Marketing Communications, Investor Relations, and Strategy and Business Development.  Mr. Cimino also managed Kodak's Digital Health Imaging Business.  Mr. Cimino holds a Bachelor's degree in Biology from the State University of New York at Geneseo.

Dr. Adeoye (Oye) Olukotun, M.D., MPH, FACC, FAHA, Chief Executive Officer of CardioVax, Inc.

Dr. Adeoye Olukotun has been a director of BioClinica since August 2008.  Since January 2006, Dr. Olukotun is the Chief Executive Officer of CardioVax Inc., a biotechnology company focused on developing innovative cardiovascular therapies.  In September 2004, Dr. Olukotun co-founded VIA Pharmaceuticals and served as the Chief Medical Officer from the company’s formation until December 2008. He is a Board Certified Cardiologist and has more than twenty-five years of experience in clinical research and drug development in the pharmaceutical industry. Dr. Olukotun has been instrumental in the submission of more than fourteen New Drug Applications, Premarket Authorization Applications, and 510k Applications. Dr. Olukotun also played leading roles in the SAVE study involving captopril (Capoten®) and the WOSCOPS, LIPID and CARE studies of pravastatin (Pravachol®). He has published more than fifty articles in peer-reviewed scientific journals. Before CardioVax and VIA, Dr. Olukotun founded CR Strategies, LLC, a clinical research and development consulting firm in Princeton, NJ, and served as its Chief Executive Officer from 2000 to 2003. He also was Chief Medical Officer of Esperion Therapeutics, Inc., a cardiovascular drug development company, until its acquisition by Pfizer in 2004. From 1996 to 2000, Dr. Olukotun was Vice President of Medical and Regulatory Affairs and Chief Medical Officer of Mallinckrodt, Inc. Prior to joining Mallinckrodt, Dr. Olukotun spent fourteen years at Bristol-Myers Squibb Company, where he served as Vice President of two divisions focused on cardiovascular research, and was involved in the clinical development of several cardiovascular and lipid-regulating agents. Dr. Olukotun received his MD degree from Albert Einstein College of Medicine, New York and obtained a MPH degree from Harvard University School of Public Health, Boston. He is a Fellow of the American College of Cardiology as well as the American Heart Association.  He is a member of the Boards of Directors of the publicly traded biotechnology companies, Icagen, Inc. of Durham, North Carolina and SemBioSys Genetics, Inc. of Calgary, Alberta, Canada and privately held Milestone Pharmaceuticals Inc. of Montreal, Canada.

David M. Stack, Chief Executive Officer of Pacira Pharmaceuticals, Inc.; Managing Director of MPM Capital and Managing Partner, Stack Pharmaceuticals, Inc.

Mr. Stack has been a director of BioClinica since January 2000.  Mr. Stack was appointed President, Chief Executive Officer of Pacira Pharmaceuticals, Inc. in November 2007 and is Managing Director of MPM Capital, the largest health venture capital firm dedicated to healthcare investment, since May 2005, and is also the Managing Partner of Stack Pharmaceuticals, Inc., a commercialization, marketing and strategy firm serving emerging healthcare companies.  Mr. Stack has been with Stack Pharmaceuticals since September 2004.  From September 2001 until August 2004, he was President, Chief Executive Officer and Director for The Medicines Company (NASDAQ: MDCO).  Prior to The Medicines Company, he was also the President of Stack Pharmaceuticals, Inc., where MDCO was one of the primary customers.  From May 1995 to December 1999, Mr. Stack served as the President and General Manager of Innovex Inc., responsible for the Americas.  Innovex Inc. was a commercial solutions company offering a full range of marketing, sales and clinical research capabilities to pharmaceutical and biotechnology customers.  From April 1993 to May 1995, Mr. Stack was the Vice President of Business Development and Marketing for Immunomedics, Inc., a biopharmaceutical focusing on monoclonal antibodies in infectious disease and oncology.  From May 1992 to March 1993, Mr. Stack had been the Director of Business Development and Planning for Infectious Disease, Oncology and Virology of Roche Laboratories where he was the Therapeutic World Leader for Infectious Disease.  Prior to that, he held various positions with Roche Laboratories for approximately 11 years, and was a retail and hospital pharmacist for three years after graduating from Albany College of Pharmacy.